{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["27 Suppl 4"],"submitter":["Zargar AH"],"funding":["Zydus Healthcare Limited"],"pubmed_abstract":["In India, the increasing prevalence of diabetes and obesity poses a significant threat towards a surge in the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). Concomitant with the evolving guidelines, there is a need to direct and spread awareness among practicing diabetologists to identify and screen high-risk individuals for MASLD for timely management. Its asymptomatic nature and the evolving guidelines on diagnosis have hindered the precise estimates of MASLD in the high-risk group of individuals in a clinical setting. Therefore, an expert panel of diabetologists from India convened to review, discuss and document the approach towards screening, diagnosis and management of MASLD. Serum biomarkers"],"journal":["Diabetes, obesity & metabolism"],"pagination":["3-20"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12150358"],"repository":["biostudies-literature"],"pubmed_title":["Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective."],"pmcid":["PMC12150358"],"pubmed_authors":["Majumdar A","Sanyal D","Das S","Saboo BD","Mehrotra RN","Zargar AH","Maheshwari A","Seshadri KG","Mohan V","Bhattacharyya A","Dasgupta A","Agarwal SC","Goswami S","Joshi SR","Shaikh SS","Sahay RK","Kapoor N","Deshpande NR","Kant S","Talwalkar PG","Ghosh S","Sethi BK","Lakhani OJ","Shukla R","Kalra P","Panikar VK","Phatak SR","G S","Bhansali A","Aravind SR"],"additional_accession":[]},"is_claimable":false,"name":"Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective.","description":"In India, the increasing prevalence of diabetes and obesity poses a significant threat towards a surge in the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). Concomitant with the evolving guidelines, there is a need to direct and spread awareness among practicing diabetologists to identify and screen high-risk individuals for MASLD for timely management. Its asymptomatic nature and the evolving guidelines on diagnosis have hindered the precise estimates of MASLD in the high-risk group of individuals in a clinical setting. Therefore, an expert panel of diabetologists from India convened to review, discuss and document the approach towards screening, diagnosis and management of MASLD. Serum biomarkers","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2026-04-08T14:51:08.479Z","creation":"2026-04-08T03:51:46.718Z"},"accession":"S-EPMC12150358","cross_references":{"pubmed":["40457532"],"doi":["10.1111/dom.16496"]}}